The antibody from Chicago-based Immunartes is designed to neutralize the immune-evasive mechanisms of Staphylococcus aureus.

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Dr. Saef Izzy, Associate Professor of Neurology at Harvard Medical School, commented, “Treatment with nasal anti-CD3 not only dampened microglial activation but also led to marked improvements in ...

Shares of biotech Summit Therapeutics ( SMMT 9.31%) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...